<DOC>
	<DOC>NCT01470989</DOC>
	<brief_summary>This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combined extension 3 study for any new gouty arthritis flare on demand with one subcutaneous (s.c.) injection of canakinumab 150 mg.</brief_summary>
	<brief_title>Î²-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Gouty</mesh_term>
	<criteria>Patients who have completed the second extension studies CACZ885H2356E2 or CACZ885H2357E2 Patients treated with canakinumab in the core studies or subsequent extensions Pregnant or nursing (lactating) women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>gouty arthritis</keyword>
</DOC>